LBRX — LB Pharmaceuticals Inc

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

El: kaydır · Tekerlek: yakınlaştır · Sağ eksen sürükle/tekerlek: fiyat ölçeği · Alt eksen sürükle/tekerlek: tarih ölçeği · Çift tık: otomatik ölçek · Esc iptal